These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 33081987)
1. Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency. Boutin S; Maltais R; Roy J; Poirier D Eur J Med Chem; 2021 Jan; 209():112909. PubMed ID: 33081987 [TBL] [Abstract][Full Text] [Related]
2. Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10. Boutin S; Roy J; Maltais R; Alata W; Calon F; Poirier D Bioorg Med Chem Lett; 2018 Dec; 28(22):3554-3559. PubMed ID: 30297283 [TBL] [Abstract][Full Text] [Related]
3. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Djigoué GB; Kenmogne LC; Roy J; Poirier D Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3). Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056 [TBL] [Abstract][Full Text] [Related]
5. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors. Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028 [TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone. Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)). Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055 [TBL] [Abstract][Full Text] [Related]
8. A- and D-Ring Structural Modifications of an Androsterone Derivative Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3: Chemical Synthesis and Structure-Activity Relationships. Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D J Med Chem; 2019 Aug; 62(15):7070-7088. PubMed ID: 31268309 [TBL] [Abstract][Full Text] [Related]
9. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Bydal P; Luu-The V; Labrie F; Poirier D Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors. Sancéau JY; Maltais R; Zhou M; Lin SX; Poirier D J Steroid Biochem Mol Biol; 2024 Sep; 242():106544. PubMed ID: 38754521 [TBL] [Abstract][Full Text] [Related]
11. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines. Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782 [TBL] [Abstract][Full Text] [Related]
12. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Vicker N; Lawrence HR; Allan GM; Bubert C; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV ChemMedChem; 2006 Apr; 1(4):464-81. PubMed ID: 16892382 [TBL] [Abstract][Full Text] [Related]
13. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives. Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of type 1 17beta-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol. Tremblay MR; Boivin RP; Luu-The V; Poirier D J Enzyme Inhib Med Chem; 2005 Apr; 20(2):153-63. PubMed ID: 15968820 [TBL] [Abstract][Full Text] [Related]
15. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Maltais R; Fournier MA; Poirier D Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3. Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282 [TBL] [Abstract][Full Text] [Related]
17. Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors. Tremblay MR; Lin SX; Poirier D Steroids; 2001 Nov; 66(11):821-31. PubMed ID: 11576622 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships. Bydal P; Auger S; Poirier D Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411 [TBL] [Abstract][Full Text] [Related]
19. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Laplante Y; Cadot C; Fournier MA; Poirier D Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543 [TBL] [Abstract][Full Text] [Related]
20. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]